MIRA Pharmaceuticals Announces Its Data From Exploratory Pilot Of SKNY-1 Shows Reductions In Body Weight, Fat Mass
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics, today announced initial positive proof-of-concept results
Share
Why It Matters
MIRA tested a new medicine that helped people lose weight and fat. When early tests look good, it shows the company's idea might actually work in real patients.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.